Latest News & Features
Big Pharma
A combination of patents, SPCs and regulatory exclusivities should be considered carefully in order to maximise the exclusivity available for cell therapies, as Glyn Truscott of Elkington + Fife explains. 22 December 2016
Big Pharma
Natalia Gulyaeva and Maria Sedykh of Hogan Lovells look at the main drivers of collaboration in the pharmaceutical sector and the legal issues to keep in mind when handling partnerships in Russia. 15 December 2016
Americas
Anyone seeking a deal with a life sciences company must understand the value and potential risks of its IP, as Karen Mangasarian and Ryan Murphey of Ropes & Gray explain. 6 December 2016
Europe
Intellectual property in the life sciences arena can be an attractive investment target, but a long process of evaluation must take place first, cautions Dimitar Georgiev, founder and CEO of Paralax Life Sciences. 24 November 2016
Americas
India’s position on patenting genes borrows heavily from that of the US, but will the status quo change? Swarup Kumar of Remfry & Sagar reports. 17 November 2016
Big Pharma
To overcome a crowded patent market, a potential solution is to seek a declaration of obviousness, which has a basis in UK law stemming from Arrow Generics v Merck. Richard Roberts of Potter Clarkson reports. 8 November 2016
Big Pharma
The IP Life Sciences Exchange, an event for senior IP decision-makers from the life sciences sector, will take place on November 15 and 16 in Munich, Germany. LSIPR previews some of the most interesting sessions. 7 November 2016
Americas
Two bodies are responsible for examining biotech patent applications in Brazil, but this approach causes problems, as Marcelo Oliveira de Souza and Antonio Alexandre Moura dos Santos of Di Blasi, Parente & Associados report. 25 October 2016
Europe
The UK’s vote to leave the EU may allow Britain to replace the SPC regulation—an often-criticised piece of law—and take a fresh approach to the system governing these rights, say Paul England and Matthew Royle of Taylor Wessing. 20 October 2016
Africa
With specialist IP providers offering post-M&A services at lower cost than traditional law firms, have clients been overspending in the past? Melissa Pillote on behalf of Dennemeyer reports. 18 October 2016